Rare Disease Drug Shows Long-Term Safety
Blueprint Medicines, a Sanofi company, has released four-year data from a study on its drug AYVAKIT®. The results show sustained benefit and long-term safety for patients with indolent systemic mastocytosis (ISM), a rare blood disorder.
Indolent systemic mastocytosis (ISM) is the most common form of a rare blood disorder where the body accumulates an excess of mast cells, leading to a wide range of debilitating symptoms including skin lesions, gastrointestinal issues, brain fog, and potentially life-threatening anaphylaxis. The drug, AYVAKIT (avapritinib), is a targeted therapy that potently and selectively inhibits KIT D816V, a genetic mutation that is the primary cause of the disease in about 95% of cases. This mechanism allows the drug to treat the underlying cause of ISM, rather than just managing its symptoms. Prior to this drug's approval, there were no specific treatments for ISM, leaving patients to rely on supportive care like antihistamines to manage their symptoms. Many lived in constant fear of triggers that could provoke severe reactions, significantly impacting their daily lives. The U.S. Food and Drug Administration approved AYVAKIT for adults with indolent systemic mastocytosis in May 2023, making it the first and only approved medicine for this condition. The approval was based on the PIONEER study, the largest clinical trial ever conducted for the disease. The four-year follow-up data from the PIONEER study demonstrated that patients experienced continued improvement in their overall symptoms and quality of life. The safety profile remained consistent and was well-tolerated, with only 3% of participants discontinuing the trial due to treatment-related adverse events over a median follow-up of nearly four years. Real-world data presented at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting supported the clinical trial findings, showing meaningful symptom benefits for patients receiving the therapy in community practice settings. In the long-term study, the most common treatment-related adverse events were mild, with edema being the most frequent. Importantly, no cases of intracranial hemorrhage, a serious potential side effect, were reported in ISM patients receiving AYVAKIT during the PIONEER study.
